Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

1. Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes Full Text available with Trip Pro

: 31377056 Clinical Trial. References REFERENCES Nadeau KJ, Regensteiner JG, Bauer TA, et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010;95(2):513-521. . Bjornstad P, Maahs DM, Duca LM, et al. Estimated insulin sensitivity predicts incident micro- and macrovascular complications in adults with type 1 diabetes over 6 years: the coronary artery calcification in type 1 diabetes study. J Diabetes Complications. 2016;30 (...) Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several

2021 EvidenceUpdates

2. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial

Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2021 Jan;9(1):32-45. doi: 10.1016/S2213-8587(20)30367-3. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA, Australia; South Australian Health and Medical (...) ] 2-h glucose 7·8-11·0 mmol/L) or newly diagnosed type 2 diabetes (provided OGTT 2-h glucose ≤15·0 mmol/L) were enrolled in a lifestyle programme and randomly assigned (1:1) to receive an intramuscular injection of testosterone undecanoate (1000 mg) or placebo at baseline, 6 weeks, and then every 3 months for 2 years. Randomisation was done centrally, including stratification by centre, age group, waist circumference, 2-h OGTT glucose, smoking, and first-degree family history of type 2 diabetes

2021 EvidenceUpdates

3. Handout on type 2 diabetes in youth for medical students or residents

Handout on type 2 diabetes in youth for medical students or residents application/vnd.openxmlformats-officedocument.wordprocessingml.document

2021 Pediatric Endocrine Society

4. A balancing act: GLP-1 receptor agonists for non-diabetic obesity

Association’s recognition of obesity as a disease in 2013, signal a trend towards a more nuanced understanding of the multifactorial nature of the disease, reducing blame and stigmatization and opening doors for greater investment in therapy, including new medications like GLP-1 agonists. 7 GLP-1 agonists are a promising drug class originally developed for the treatment of type 2 diabetes, but recently shown to be effective for weight loss in non-diabetic patients with obesity or overweight BMI when given (...) intervention significantly improved weight maintenance at 56 weeks when compared with controls (who received placebo and lifestyle intervention) in overweight and obese individuals who had already lost at least 5% of initial body weight during a low-calorie diet prior to randomization. 13 Semaglutide, another GLP-1 agonist already approved for type 2 diabetes treatment, is also in ongoing trials for obesity treatment in patients without diabetes 14 and may provide a greater weight loss benefit than

2021 Clinical Correlations

5. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial Full Text available with Trip Pro

RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Feb;23(2):569-580. doi: 10.1111/dom.14254. Epub 2020 Dec 6. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division (...) with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial Mark A Espeland et al. Diabetes Obes Metab . 2021 Feb . Show details Display options Display options Format Diabetes Obes Metab Actions . 2021 Feb;23(2):569-580. doi: 10.1111/dom.14254. Epub 2020 Dec 6. Authors , , , , , , , , , , , , Affiliations 1 Division of Gerontology and Geriatric Medicine, Wake Forest School

2021 EvidenceUpdates

6. Benefits of CPAP on glycemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnea: a meta-analysis

. 2021 Feb;23(2):540-548. doi: 10.1111/dom.14247. Epub 2020 Dec 2. Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis , , , Affiliations Expand Affiliations 1 Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, China. 2 Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Medical College, Xi'an (...) Jiaotong University, Xi'an, China. PMID: 33146450 DOI: Item in Clipboard Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis Wenli Shang et al. Diabetes Obes Metab . 2021 Feb . Show details Display options Display options Format Diabetes Obes Metab Actions . 2021 Feb;23(2):540-548. doi: 10.1111/dom.14247. Epub 2020 Dec 2. Authors , , , Affiliations 1 Department of Respiratory

2021 EvidenceUpdates

7. Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis Full Text available with Trip Pro

/journal.pmed.1003434. eCollection 2020 Nov. Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis , , , , , , , , Affiliations Expand Affiliations 1 Center for Research in Indigenous Health, Wuqu' Kawoq, Tecpán, Guatemala. 2 Division of Hospital Medicine, Department of Internal Medicine, National Clinician Scholars Program, University of Michigan, Ann Arbor, Michigan, United States of America. 3 Medicine-Pediatrics Residency (...) with type 2 diabetes in LMICs. Methods and findings: We searched Ovid MEDLINE, Cochrane Library, EMBASE, African Index Medicus, LILACS, and Global Index Medicus from inception of each database through February 24, 2020. We included randomized controlled trials (RCTs) of health system interventions targeting adults with type 2 diabetes in LMICs. Eligible studies reported at least 1 of the following outcomes: glycemic change, mortality, quality of life, or cost-effectiveness. We conducted a meta-analysis

2021 EvidenceUpdates

8. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

options Format Share Permalink Copy Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, Department of Internal Medicine, University (...) in Clipboard Randomized Controlled Trial Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial Darren K McGuire et al. Lancet Diabetes Endocrinol . 2020 Dec . Show details Display options Display options Format Lancet Diabetes Endocrinol Actions . 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2. Authors , , , , , , , , , , , , , , , Affiliations 1 Division

2020 EvidenceUpdates

9. Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review

Actions . 2020 Nov 7;e13817. doi: 10.1111/ijcp.13817. Online ahead of print. Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Chronic Diseases Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. 2 Department of Data Science, King Hussein Faculty for Computer Sciences, Princess (...) diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review Ayla M Tourkmani et al. Int J Clin Pract . 2020 . Show details Display options Display options Format Int J Clin Pract Actions . 2020 Nov 7;e13817. doi: 10.1111/ijcp.13817. Online ahead of print. Authors , , , , , , , , , , , , , , , Affiliations 1 Chronic Diseases Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. 2

2020 EvidenceUpdates

10. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study

options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Nov 9;dc200358. doi: 10.2337/dc20-0358. Online ahead of print. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Centers for Disease Control and Prevention, Atlanta (...) of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study Ping Zhang et al. Diabetes Care . 2020 . Show details Display options Display options Format Diabetes Care Actions . 2020 Nov 9;dc200358. doi: 10.2337/dc20-0358. Online ahead of print. Authors , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1 Centers for Disease Control and Prevention, Atlanta, GA paz2

2020 EvidenceUpdates

11. Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE Full Text available with Trip Pro

risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. 2 Department of Internal Medicine and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 3 HCA Midwest Health Heart and Vascular Institute, Overland Park, Kansas, USA. 4 Scripps Whittier Diabetes Institute, San Diego (...) high-risk individuals with advanced type 2 diabetes in DEVOTE Simon Heller et al. Diabetes Obes Metab . 2020 Dec . Show details Display options Display options Format Diabetes Obes Metab Actions . 2020 Dec;22(12):2248-2256. doi: 10.1111/dom.14208. Authors , , , , , , , , , , , , , Affiliations 1 Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. 2 Department of Internal Medicine and Department of Population and Data Sciences, University of Texas Southwestern Medical

2020 EvidenceUpdates

12. The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis Full Text available with Trip Pro

The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) /dom.14221. Online ahead of print. The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis , , , , Affiliations Expand Affiliations 1 School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. 2 Institute of Diabetes Endocrinology and Obesity, King's Health Partners, London, UK. 3 Diabetes Research Group, Weston Education Centre, King's

2020 EvidenceUpdates

13. A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT Full Text available with Trip Pro

A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) , Ghadah Aldubaikhi 4 , Ben Glover 1 , Joanne Lord 6 , Olu Onyimadu 6 , Emmanuela Falaschetti 5 , Natalia Klimowska-Nassar 5 , Hutan Ashrafian 1 , James Byrne 7 , Julian P Teare 1 1 Department of Surgery and Cancer, St Mary’s Hospital, Imperial College London, London, UK 2 National Institute for Health Research Southampton Biomedical Research Centre, Southampton Centre for Biomedical Research, Southampton General Hospital, Southampton, UK 3 Section of Investigative Medicine, Division of Diabetes

2020 NIHR HTA programme

14. Continuous glucose monitoring in pregnant women with type 1 diabetes

Continuous glucose monitoring in pregnant women with type 1 diabetes SHTG Adaptation | 1 SHTG Adaptation 01 November 2020 In response to an enquiry from the Scottish Diabetes Group (SDG) Continuous glucose monitoring in pregnant women with type 1 diabetes* *adaptation for NHSScotland of guidance published by Health Technology Wales Recommendations for NHSScotland Continuous glucose monitoring (CGM) should be offered to all pregnant women with type 1 diabetes (T1DM). The case for adopting CGM (...) in 2017 with the section on pregnancy currently being reviewed) includes a recommendation that: “Continuous glucose monitoring may be considered in women with type 1 and type 2 diabetes.” In June 2017, the Scottish Government wrote to Health Boards announcing £10m funding over 5 years to increase insulin pump use and encourage the implementation of CGM systems 4 . In a Scottish Government letter dated July 2019, those considered highest priority for commencement of CGM included pregnant women

2020 SHTG Advice Statements

15. Comprehensive Type 2 Diabetes Management Algorithm

Comprehensive Type 2 Diabetes Management Algorithm ENDOCRINE PRACTICE Vol 26 No. 1 January 2020 107 CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY Alan J. Garber, MD, PhD, MACE 1 ; Yehuda Handelsman, MD, FACP , FNLA, MACE 2 ; George Grunberger, MD, FACP , FACE 3 ; Daniel Einhorn, MD, FACP , FACE 4 ; Martin J. Abrahamson, MD 5 ; Joshua I. Barzilay (...) acid; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density- lipoprotein cholesterol; HeFH = heterozygous famil- ial hypercholesterolemia; LDL-C = low-density-lipo- protein cholesterol; LDL-P = low-density-lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; PCSK9 = proprotein conver- tase subtilisin-kexin type 9 serine protease; RCT = randomized controlled

2020 American Association of Clinical Endocrinologists

16. An Early-Onset Subgroup of Type 2 Diabetes: A Multigenerational, Prospective Analysis in the Framingham Heart Study

Subgroup of Type 2 Diabetes: A Multigenerational, Prospective Analysis in the Framingham Heart Study , , , , , , , Affiliations Expand Affiliations 1 Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, MD jechouf1@jhmi.edu. 2 Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland. 3 Department of Biostatistics, Boston University School of Public Health, Boston, MA. 4 Division of Cardiovascular Medicine (...) Institute, Cedars Sinai Medical Center, Los Angeles, CA. PMID: 33033069 DOI: Item in Clipboard An Early-Onset Subgroup of Type 2 Diabetes: A Multigenerational, Prospective Analysis in the Framingham Heart Study Justin B Echouffo-Tcheugui et al. Diabetes Care . 2020 . Show details Display options Display options Format Diabetes Care Actions . 2020 Oct 8;dc191758. doi: 10.2337/dc19-1758. Online ahead of print. Authors , , , , , , , Affiliations 1 Division of Endocrinology, Diabetes and Metabolism

2020 EvidenceUpdates

17. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Full Text available with Trip Pro

RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 7. doi: 10.1111/dom.14189. Online ahead of print. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Oslo (...) cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Kåre I Birkeland et al. Diabetes Obes Metab . 2020 . Show details Display options Display options Format Diabetes Obes Metab Actions . 2020 Sep 7. doi: 10.1111/dom.14189. Online ahead of print. Authors , , , , , , , , , , , , , , Affiliations 1 Oslo University Hospital and University of Oslo, Oslo, Norway. 2 AstraZeneca

2020 EvidenceUpdates

18. Efficacy and safety of polyethylene glycol loxenatide (PEX168) monotherapy in type 2 diabetes patients: a multicenter, randomized, double-blind, placebo-controlled, phase 3a clinical trial. Full Text available with Trip Pro

Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 23. doi: 10.1111/dom.14198. Online ahead of print. Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial , , , , , , , , , , , Affiliations Expand Affiliations 1 China-Japan Friendship Hospital, Beijing, China. 2 Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical University (...) in Clipboard Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial Ying Shuai et al. Diabetes Obes Metab . 2020 . Show details Display options Display options Format Diabetes Obes Metab Actions . 2020 Sep 23. doi: 10.1111/dom.14198. Online ahead of print. Authors , , , , , , , , , , , Affiliations 1 China-Japan Friendship Hospital, Beijing, China. 2 Department of Endocrinology

2020 EvidenceUpdates

19. Dapagliflozin (Forxiga): no place in type 1 diabetes

Dapagliflozin (Forxiga): no place in type 1 diabetes Prescrire IN ENGLISH - Spotlight ''Dapagliflozin (Forxiga°): no place in type 1 diabetes '', 1 November 2020 {1} {1} {1} | | > > > Dapagliflozin (Forxiga°): no place in type 1 diabetes Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Dapagliflozin (Forxiga°): no place in type 1 diabetes (...) Dapagliflozin (Forxiga°) has no demonstrated efficacy with regard to the clinical complications of type 1 diabetes and it carries a risk of sometimes serious adverse effects. Dapagliflozin is one of the gliflozin group of hypoglycaemic drugs, which lower blood glucose levels by increasing excretion of glucose in the urine. In the European Union, the glifozins were first authorised for patients with type 2 diabetes. In that setting, their harm-benefit balance is unfavourable, mainly due to the risk

2020 Prescrire

20. Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years Full Text available with Trip Pro

: 10.1111/dom.14218. Online ahead of print. Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years , , , , Affiliations Expand Affiliations 1 Leicester Real World Evidence Unit, Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK. 2 Novo Nordisk Region Europe Pharmaceuticals A/S, København, Denmark. 3 Department of Diabetes Medicine, National Institute for Health Research (...) Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily

2020 EvidenceUpdates